Construction and Analysis of a Risk Prediction Model for Acute Myocardial Infarction Based on Spatiotemporal Heterogeneous Data

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-85
SponsorBeijing Anzhen Hospital

About this trial

Acute myocardial infarction (AMI), as the leading cause of death among cardiovascular diseases, has its diagnosis and treatment efficiency directly affecting survival. Although the current diagnosis and treatment system has significantly improved in-hospital outcomes, delays in seeking medical care due to patients' insufficient awareness and out-of-hospital deaths are common, representing the biggest bottleneck in improving diagnostic and treatment capabilities. This study takes intelligent-assisted diagnosis of AMI as the entry point and proposes a technical approach that combines a deep learning algorithm based on 12-lead electrocardiograms with wearable monitoring devices. By utilizing morphological feature extraction and deep learning models, it aims to achieve early identification and warning of AMI. The study plans to build a multi-center AMI long-term follow-up cohort covering the Beijing area based on spatiotemporal heterogeneous data. By integrating and forming a precise high-risk cohort of 3,000 acute myocardial infarction cases, it seeks to construct an AMI risk prediction model that combines deep learning with a retrieval-augmented generative expert system, breaking through bottlenecks in ECG recognition and temporal prediction, enhancing model generalization and transferability. Ultimately, it will support the application of wearable devices, shorten pre-hospital delays, achieve early warning and precise diagnosis of AMI, reduce reinfarction and cardiac-related mortality, and carry significant clinical and public health importance.

Eligibility criteria

Qualifiers

Multivessel coronary artery disease (defined as ≥50% stenosis in at least 2 coronary artery regions, including the left main coronary artery)

Previous myocardial infarction

Patients with diabetes currently undergoing glucose-lowering treatment

Chronic kidney disease (CKD) defined as an estimated glomerular filtration rate <60 mL/min/1.73 m² with a known history of chronic kidney disease or biomarkers indicating chronic kidney damage

Disqualifiers

Researchers consider diseases or conditions that are not suitable for participation in this study (such as mental illness, significant cognitive impairment, neurodegenerative diseases, advanced malignant tumors) or situations (such as inability to communicate well with researchers in the local language, unwillingness to comply with study procedures/instructions, inability to understand study-specific training, physically fragile and vulnerable subjects).

Participation in a clinical trial involving drugs or devices within 3 months prior to enrollment.

Women who are pregnant, planning to become pregnant, or breastfeeding.

Known life-threatening diseases with an expected survival of less than 12 months.

Trial design

Treatments tested in this trial

  • Acute Myocardial Infarction Risk Prediction Model

Treatment groups

No treatment groups listed

Locations

This trial has no locations

Sponsors and collaborators